5 results match your criteria: "Bristol Oncology and Haematology Centre[Affiliation]"
J Clin Oncol
January 2021
University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Bone Marrow Transplant
June 2019
Department of Haematology, Bristol Oncology and Haematology Centre, Bristol, UK.
Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing number of management strategies ranging from observation through to stem cell transplantation. There has been an exciting expansion in novel agents to treat FL, but at present there is not a universally accepted standard of care in the relapse setting. Decision-making can be difficult for the clinician as there is a paucity of data to compare the various relapse therapies available.
View Article and Find Full Text PDFJ Clin Oncol
May 2018
Paola Di Nardo, Bristol Oncology and Haematology Centre, Bristol, United Kingdom; and Alfredo Addeo, University Hospital Geneva, Geneva, Switzerland.
Palliat Med
July 2011
Department of Palliative Medicine, University of Bristol, Bristol Oncology and Haematology Centre, Bristol BS2 8ED, UK.
Background: Opioid use in patients with renal impairment can lead to increased adverse effects. Opioids differ in their effect in renal impairment in both efficacy and tolerability. This systematic literature review forms the basis of guidelines for opioid use in renal impairment and cancer pain as part of the European Palliative Care Research Collaborative's opioid guidelines project.
View Article and Find Full Text PDFClin Oncol (R Coll Radiol)
April 2011
Bristol Oncology and Haematology Centre, Horfield Road, Bristol, UK.
Aims: The most effective sequence of tamoxifen and both steroidal (SAIs) and non-steroidal aromatase inhibitors (NSAIs) has been extensively studied in the adjuvant setting. However, treatments for women who have failed initial aromatase inhibitor therapy in the metastatic setting have received relatively little attention. A systematic review was undertaken to assess the use of SAIs and NSAIs in metastatic breast cancer.
View Article and Find Full Text PDF